Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial

MUNICH, June 16, 2025 /PRNewswire/ -- Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus (HSV).

This placebo-controlled study is designed to assess the safety, efficacy, and pharmacokinetics of once-weekly oral dosing of IM-250 in patients with recurrent genital herpes. The successful completion of Phase 1b enrollment marks a key inflection point in the program, supporting the continued clinical development of IM-250 and its potential to reshape a market that has seen little therapeutic innovation in over four decades.

"Completing Phase 1b enrollment represents a significant milestone not only for our clinical program but also for patients who continue to face the burden of recurrent genital herpes with limited treatment options," said Dr. Anja Glaessing, Head of Medical Affairs at Innovative Molecules.

Read full article.